ENPP1 Deficiency

Synonyms

Generalized Arterial Calcification of Infancy, GACI, Autosomal Recessive Hypophosphatemic Rickets Type 2, ARHR2, ENPP1-related Ectonucleotide Pyrophosphatase-Phosphodiesterase 1 Deficiency,

Overview

ENPP1 Deficiency is a rare, progressive genetic disorder characterized by the body’s inability to properly regulate inorganic pyrophosphate (PPi) levels. This leads to a severe imbalance: causing excessive calcium buildup in soft tissues and blood vessels, while paradoxically resulting in weakened, undermineralized bones.

Symptoms

Symptoms vary widely across age groups but commonly include bone and joint pain, severe fatigue, hearing loss, and cardiovascular complications. 

Causes

ENPP1 deficiency is a rare genetic disorder caused by loss-of-function mutations in the ENPP1 gene. These mutations impair the body’s ability to produce the ENPP1 enzyme, leading to dangerously low levels of inorganic pyrophosphate. This deficiency disrupts mineralization, causing calcium to build up in soft tissues and blood vessels. 

Prevention

Because ENPP1 deficiency is a genetic, autosomal recessive disorder, true “prevention” of the disease focuses on family planning, genetic carrier screening, and proactive medical management to prevent life-threatening complications rather than reversing the mutation.

Diagnosis

Diagnosing ENPP1 deficiency relies on a combination of genetic sequencing, bloodwork, and medical imaging. Because symptoms can range widely depending on the age of onset, identifying mutations in the gene is the only definitive way to confirm this rare disorder. 

Prognosis

ENPP1 Deficiency is a progressive genetic metabolic disorder caused by mutations in the ENPP1 gene, leading to abnormal calcium-phosphate calcification throughout the body. Prognosis depends on age of onset, with severe infantile cases carrying a 50% mortality rate, while surviving patients face lifelong, chronic musculoskeletal and cardiovascular complications. 

Treatment

Currently, there are no approved therapies that address the underlying cause of ENPP1 deficiency. Standard care relies on multidisciplinary symptom management, including bisphosphonates to inhibit calcification, phosphate and vitamin D supplementation for rickets, and surgery for tissue removal. Enzyme replacement therapies (like INZ-701) are currently in late-stage clinical trials.